Rituximab and Cytokine Release Syndrome
Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated with cytokine release syndrome (CRS) is a ver...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2012-03-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/337577 |
| _version_ | 1811320897864204288 |
|---|---|
| author | Hrishikesh S. Kulkarni Pashtoon Murtaza Kasi |
| author_facet | Hrishikesh S. Kulkarni Pashtoon Murtaza Kasi |
| author_sort | Hrishikesh S. Kulkarni |
| collection | DOAJ |
| description | Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated with cytokine release syndrome (CRS) is a very rare entity associated with the use of rituximab and carries a very high morbidity and case fatality rate. Cases of CRS reported within the literature are of patients with a very high tumor burden leading to a catastrophic cascade of events. We report the case of a patient having post-transplant lymphoproliferative disorder who died of fatal lactic acidosis and CRS within 24 h of receiving rituximab. Understanding the pathophysiology of such cases and identifying patients at risk may help to possibly avert this life-threatening complication. |
| first_indexed | 2024-04-13T13:08:30Z |
| format | Article |
| id | doaj.art-9009e422aa804af5b200b2bf205d1ced |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-04-13T13:08:30Z |
| publishDate | 2012-03-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-9009e422aa804af5b200b2bf205d1ced2022-12-22T02:45:42ZengKarger PublishersCase Reports in Oncology1662-65752012-03-015113414010.1159/000337577337577Rituximab and Cytokine Release SyndromeHrishikesh S. KulkarniPashtoon Murtaza KasiRituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated with cytokine release syndrome (CRS) is a very rare entity associated with the use of rituximab and carries a very high morbidity and case fatality rate. Cases of CRS reported within the literature are of patients with a very high tumor burden leading to a catastrophic cascade of events. We report the case of a patient having post-transplant lymphoproliferative disorder who died of fatal lactic acidosis and CRS within 24 h of receiving rituximab. Understanding the pathophysiology of such cases and identifying patients at risk may help to possibly avert this life-threatening complication.http://www.karger.com/Article/FullText/337577RituximabCytokine release syndromeSystemic inflammatory response syndromeMortalityFatalityLactic acidosisPost-transplant lymphoproliferative disorder |
| spellingShingle | Hrishikesh S. Kulkarni Pashtoon Murtaza Kasi Rituximab and Cytokine Release Syndrome Case Reports in Oncology Rituximab Cytokine release syndrome Systemic inflammatory response syndrome Mortality Fatality Lactic acidosis Post-transplant lymphoproliferative disorder |
| title | Rituximab and Cytokine Release Syndrome |
| title_full | Rituximab and Cytokine Release Syndrome |
| title_fullStr | Rituximab and Cytokine Release Syndrome |
| title_full_unstemmed | Rituximab and Cytokine Release Syndrome |
| title_short | Rituximab and Cytokine Release Syndrome |
| title_sort | rituximab and cytokine release syndrome |
| topic | Rituximab Cytokine release syndrome Systemic inflammatory response syndrome Mortality Fatality Lactic acidosis Post-transplant lymphoproliferative disorder |
| url | http://www.karger.com/Article/FullText/337577 |
| work_keys_str_mv | AT hrishikeshskulkarni rituximabandcytokinereleasesyndrome AT pashtoonmurtazakasi rituximabandcytokinereleasesyndrome |